Trial Profile

Open-label single arm phase II study on pembrolizumab for recurrent primary central nervous system lymphoma (PCNSL)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications CNS cancer; Diffuse large B cell lymphoma; Lymphoma
Focus Therapeutic Use

Most Recent Events

11 May 2022 This trial has been discontinued in Austria (Date of the global end of the trial : 15-Oct-2019), according to European Clinical Trials Database record.
03 Nov 2020 This trial has been discontinued in Netherlands, according to European Clinical Trials Database record.
10 Mar 2016 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com